544,001 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Acquired by Lynx1 Capital Management LP

Lynx1 Capital Management LP purchased a new position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 544,001 shares of the company's stock, valued at approximately $8,612,000. Keros Therapeutics accounts for approximately 3.2% of Lynx1 Capital Management LP's holdings, making the stock its 8th biggest position. Lynx1 Capital Management LP owned about 1.34% of Keros Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Keros Therapeutics by 5.4% during the fourth quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company's stock worth $30,981,000 after purchasing an additional 100,691 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Keros Therapeutics by 5.5% in the 4th quarter. Geode Capital Management LLC now owns 765,436 shares of the company's stock valued at $12,120,000 after acquiring an additional 39,815 shares during the period. American Century Companies Inc. lifted its holdings in shares of Keros Therapeutics by 10.5% in the 4th quarter. American Century Companies Inc. now owns 328,920 shares of the company's stock worth $5,207,000 after acquiring an additional 31,251 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Keros Therapeutics by 7.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 279,682 shares of the company's stock valued at $4,427,000 after purchasing an additional 19,562 shares during the last quarter. Finally, Emerald Advisers LLC increased its holdings in Keros Therapeutics by 57.3% in the 4th quarter. Emerald Advisers LLC now owns 244,633 shares of the company's stock valued at $3,873,000 after purchasing an additional 89,088 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company's stock.

Insiders Place Their Bets

In other news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the company's stock in a transaction on Wednesday, April 9th. The stock was bought at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the purchase, the insider now directly owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. The trade was a 27.01 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 22.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on KROS shares. Wells Fargo & Company reduced their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, February 27th. HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Truist Financial decreased their price target on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. Piper Sandler cut their price target on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research note on Friday, January 17th. Finally, Guggenheim reaffirmed a "neutral" rating on shares of Keros Therapeutics in a report on Friday, January 17th. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $40.33.

Keros Therapeutics Stock Performance

Keros Therapeutics stock traded up $0.15 during midday trading on Friday, reaching $14.72. 377,795 shares of the company were exchanged, compared to its average volume of 807,630. The firm's 50-day simple moving average is $11.85 and its 200-day simple moving average is $26.64. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $72.37. The company has a market capitalization of $597.79 million, a price-to-earnings ratio of -2.82 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. On average, analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.